Unavailability of thymidine kinase does not preclude the use of German comprehensive prognostic index: Results of an external validation analysis in early chronic lymphocytic leukemia and comparison with MD Anderson Cancer Center model

Stefano Molica, Diana Giannarelli, Rosanna Mirabelli, Luciano Levato, Antonio Russo, Maria Linardi, Massimo Gentile, Fortunato Morabito

Research output: Contribution to journalArticle

Abstract

A comprehensive prognostic index that includes clinical (i.e., age, sex, ECOG performance status), serum (i.e., ß2-microglobulin, thymidine kinase [TK]), and molecular (i.e., IGVH mutational status, del 17p, del 11q) markers developed by the German CLL Study Group (GCLLSG) was externally validated in a prospective, community-based cohort consisting of 338 patients with early chronic lymphocytic leukemia (CLL) using as endpoint the time to first treatment (TTFT). Because serum TK was not available, a slightly modified version of the model based on seven instead of eight prognostic variables was used. By German index, 62.9% of patients were scored as having low-risk CLL (score 0-2), whereas 37.1% had intermediate-risk CLL (score 3-5). This stratification translated into a significant difference in the TTFT [HR=4.21; 95% C.I. (2.71-6.53); P

Original languageEnglish
Pages (from-to)72-77
Number of pages6
JournalEuropean Journal of Haematology
Volume96
Issue number1
DOIs
Publication statusPublished - Jan 1 2016

Keywords

  • Binet stage A patients
  • Chronic lymphocytic leukemia
  • German prognostic index
  • Prognosis

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Unavailability of thymidine kinase does not preclude the use of German comprehensive prognostic index: Results of an external validation analysis in early chronic lymphocytic leukemia and comparison with MD Anderson Cancer Center model'. Together they form a unique fingerprint.

  • Cite this